Search the Newsreel

Mindteck Q1 Results FY27: Revenue Rs 104 crore, Net Profit Rs 8 Crore

Virtual Mind Wins Unanimous Shareholder Backing for Subscription and Placing Deals

Can Bright Minds (TSX:DRUG) Keep Biotech Momentum Going?

Bright Minds Biosciences (TSX:DRUG) is gaining attention due to progress in its lead neuroscience program, BMB, a selective serotonin receptor-targeting candidate for difficult-to-treat seizure disorders. The company reported positive topline results from its BREAKTHROUGH study, demonstrating anti-seizure activity and a favorable safety profile, and …

Adage Capital (DRUG) discloses 3.41% Bright Minds Biosciences stake in latest holding

Adage Capital Management, L.P. and its affiliated entities have reported a beneficial ownership of 3.41% in Bright Minds Biosciences Inc. (DRUG) through a Schedule 13G/A filing. This stake, totaling 335,000 common shares, reflects shared voting and dispositive power among the reporting persons, including Robert …

Mindteck Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Mind CTI Ltd (MNDO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Mindteck (India) consolidated net profit declines 4.46% in the June 2026 quarter

Mindteck net profit falls 4.5% in Q1FY27 as employee costs rise

Mindteck (India) June-Quarter Consol Profit 83.6 Million Rupees

Orly Sorokin At MIND C.T.I. Exercises Options Worth $0

Orly Sorokin, Chief Business Officer at MIND C.T.I. (NASDAQ: MNDO), exercised company stock options for 0 shares, valued at $0, according to an SEC filing on August 10. The article details MIND C.T.I.'s financial performance, including a 1.78% revenue growth, a low debt-to-equity ratio …

Bright Minds Biosciences Inc (CN:DRUG) Shares Under Pressure as Biotech Sentiment Weakens and Development Risks Increase

Bright Minds Biosciences Inc (CN:DRUG) shares experienced a decline due to weakening investor sentiment in the biotechnology sector, coupled with increased development risks inherent in clinical-stage companies. The company, which focuses on psychedelic-inspired therapies for neurological and psychiatric disorders, faces challenges including clinical trial …

MIND CTI (MNDO) awards 200,000 stock options to Chief Business Officer Sorokin

MIND CTI Ltd. (MNDO) has granted Chief Business Officer Orly Sorokin 200,000 stock options with an exercise price of $1.03 per share, expiring on August 6, 2031. The options will vest in tranches over several years, starting August 6, 2028. This grant represents a …

Bright Minds Biosciences (CNSX:DRUG) - Stock Analysis

This article provides a stock analysis of Bright Minds Biosciences (CNSX:DRUG), highlighting its valuation, future growth prospects, past performance, and financial health. The company is trading significantly below its estimated fair value and its revenue is forecast to grow, but it faces risks such …

Mind Technology Inc (MIND) Earnings Forecast: Future EPS & Revenue Growth Estimates

Mind Technology Inc (MIND) currently holds an earnings forecast score of 10.00, ranking first in its industry, with analysts setting an average price target of $10.00. One analyst has issued a "Strong Buy" rating for MIND, indicating a potential upside of 89.75%. The company's …

MIND CTI Posts Higher Q2 Profit but Faces Nasdaq Compliance Deadlines

MIND CTI reported higher Q2 2026 profit despite a slight revenue slip, driven by a more profitable revenue mix and improved margins. The company is actively executing a share buyback program and completed an acquisition, but faces Nasdaq non-compliance notices regarding minimum bid price …

Bright Minds Biosciences Inc (CN:DRUG) Jumps 4.05%: neuroscience biotech's Canadian line rose to C$114 on almost no volume, a thin-trading blip rather than

Bright Minds Biosciences Inc (CN:DRUG) saw its Canadian-listed shares jump 4.05% to C$114 on August 6, 2026, though this increase is attributed to extremely low trading volume (302 shares) rather than any new company news or market re-evaluation. The article emphasizes that the movement …

MIND C.T.I. Reports Second-Quarter and First-Half 2026 Results, Updates Nasdaq Compliance Status

MIND C.T.I. announced its Q2 2026 financial results, with revenues of $4.6 million, a net income of $0.8 million, and improved operating income despite a slight revenue decline in the messaging segment. The company also addressed Nasdaq non-compliance letters regarding minimum bid price and …

Mind CTI Q2 Operating Cash Flow USD 100 Thous

Mind CTI reported an operating cash flow of USD 100 thousand for the second quarter. This financial update provides key insight into the company's recent cash generation.

Press Release: MIND CTI Reports Second Quarter 2026 Results

MIND CTI announced its financial results for the second quarter of 2026. The report details the company's performance, including key financial metrics and operational highlights for the period.

Earnings Update: Here's Why Analysts Just Lifted Their Uno Minda Limited (NSE:UNOMINDA) Price Target To ₹1,329

MIND C.T.I. Ltd. Revenue Breakdown – BOATS:MNDO

This article provides a revenue breakdown for MIND C.T.I. Ltd. (MNDO), highlighting that Europe was the largest contributor to its revenue, accounting for $11.43 million last year and $11.40 million the year before. The data is presented through TradingView, focusing on the company's financial …

Bright Minds Biosciences (DRUG) to Post Quarterly Earnings on Thursday

Bright Minds Biosciences (NASDAQ:DRUG) is scheduled to release its Q3 2026 earnings before market open on Thursday, August 13th. Analysts anticipate a loss of $1.2831 per share. The company previously reported a loss of $0.80 per share, exceeding analyst estimates by $0.06.

MIND CTI Has Until Dec. 21 to Meet Nasdaq Bid-Price Rule

MIND CTI (Nasdaq: MNDO) reported mixed Q2 2026 results with revenues slightly down but net income and operating income up. The company also announced it received two Nasdaq notifications: one for non-compliance with the minimum bid price rule, with a deadline of December 21, …

MIND CTI (NASDAQ: MNDO) grows Q2 profit and receives Nasdaq warnings

MIND CTI (NASDAQ: MNDO) reported increased profits for Q2 2026, with net income rising to $775 thousand from $483 thousand a year earlier, despite a slight decrease in revenues. The company also disclosed receiving two non-compliance warnings from Nasdaq: one for failing to meet …

MIND C.T.I. (MNDO) Earnings Date and Reports 2026

Why (DRUG) Price Action Is Critical for Tactical Trading

This article analyzes Bright Minds Biosciences Inc. (NASDAQ: DRUG) using AI models to provide trading strategies. It highlights a near-term strong sentiment influencing a mid-term neutrality toward a long-term positive bias, noting a mid-channel oscillation pattern. The analysis offers specific entry, target, and stop-loss …

REG - Mind Gym PLC - Holding(s) in Company

Virtual Mind Enters Collaboration MoU with Saudi Art Agency

Virtual Mind Holding Company Limited and Lasiaf Art Production Agency Enter Memorandum of Understanding for Strategic Partnership in Artwork Ip Business

DRUG|Bright Minds Biosciences Inc|Price:73.840|Chg%:+0.580

Bright Minds Biosciences Inc. (DRUG) shows a current price of 77.770 USD with a 5.41% increase, and a market cap of 763.08M. Analyst ratings are predominantly "Buy" with a target price of 148.557 USD, indicating a 102.78% upside. The company is focused on developing …

Virtual Mind Signs Exclusive Middle East Art IP Partnership With Saudi Agency

Mind Gym plc (MIND) Executive Chair and Co-Founder Octavius Black CBE Resigns Due to Health Issues

Perceptive Advisors LLC Sells 71,746 Shares of Bright Minds Biosciences Inc. $DRUG

Perceptive Advisors LLC reduced its stake in Bright Minds Biosciences (NASDAQ:DRUG) by 16% in the first quarter, selling 71,746 shares and retaining 377,544 shares valued at $27.5 million. Despite this, institutional investors collectively own about 40.5% of the company's stock, with several firms increasing …